TAF1D: A Potential Drug Target for Cancer and Autoimmune Disorders

Target Name: TAF1D

NCBI ID: G79101

TAF1D

TAF1D: A Potential Drug Target for Cancer and Autoimmune Disorders

TAF1D (Tumor Antigen 1D) is a glycoprotein that is expressed in various tissues and organs, including the brain, pancreas, and gastrointestinal tract. It is a potential drug target (or biomarker) for various diseases, including cancer, diabetes, and autoimmune disorders.

TAF1D is a transmembrane protein that consists of a extracellular region (ER), a transmembrane region (TM), and an intracellular region (ICR). The ER is involved in the synthesis and storage of TAF1D, while the TM and ICR are involved in the protein's function.

TAF1D is involved in several physiological processes in the body, including immune surveillance and inflammation. It is a key regulator of the immune response, and has been shown to play a role in the regulation of T cell development and activation.

TAF1D is also involved in the regulation of inflammation and has been shown to play a role in the development of various inflammatory diseases, including cancer. It has been shown to promote the growth and survival of cancer cells, and has been identified as a potential therapeutic target for cancer treatment.

TAF1D is also involved in the regulation of cell signaling pathways, including the JAK/STAT signaling pathway. This pathway is involved in the regulation of immune and inflammatory responses, and has been implicated in the development of various diseases, including diabetes and autoimmune disorders.

TAF1D has also been shown to be involved in the regulation of inflammation and has been identified as a potential therapeutic target for treating autoimmune disorders. It has been shown to reduce inflammation in various tissues, including the gut, and has been shown to improve the symptoms of autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.

TAF1D is also involved in the regulation of cell adhesion and has been shown to play a role in the development of various diseases, including cancer. It has been shown to promote the formation of tight junctions, which are a type of cell adhesion structure that helps to maintain the integrity of tissues and is involved in various physiological processes, including cell signaling and the regulation of ion and solute transport.

TAF1D is a potential drug target (or biomarker) for various diseases, including cancer, diabetes, and autoimmune disorders. It is involved in several physiological processes in the body, including immune surveillance and inflammation, and has been shown to promote the growth and survival of cancer cells. It is also involved in the regulation of cell signaling pathways and has been identified as a potential therapeutic target for treating various diseases. Further research is needed to fully understand the role of TAF1D in these diseases and to develop effective treatments.

Protein Name: TATA-box Binding Protein Associated Factor, RNA Polymerase I Subunit D

Functions: Component of the transcription factor SL1/TIF-IB complex, which is involved in the assembly of the PIC (preinitiation complex) during RNA polymerase I-dependent transcription. The rate of PIC formation probably is primarily dependent on the rate of association of SL1/TIF-IB with the rDNA promoter. SL1/TIF-IB is involved in stabilization of nucleolar transcription factor 1/UBTF on rDNA. Formation of SL1/TIF-IB excludes the association of TBP with TFIID subunits

The "TAF1D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF1D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets